Skip to content
value.today

Alvine Pharmaceuticals Inc.

Total raised
$39 M
3 rounds on record
Latest round
$6 M
Dec 2012
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Alvine Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2012$6 MNo. 3$2 to $10 million

Alvine Pharmaceuticals Inc.: Raise no. 3, Dec 2012

Investors in this round

7 investors had bought by the notice of Jan 3, 2013: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhay Joshi · Executive Officer, Director
  • David Southern · Executive Officer
  • Chaitan Khosla · Director
  • David Patrick Schnell · Director
  • Gaurav Aggarawal · Director
  • L. Patrick Gage · Director
  • Michael Patrick Powell · Director
  • Nina Patrick Kjellson · Director
  • William Patrick Ringo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Abhay Joshi, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 3, 2013. Read the notice at the SEC.

debt, optionsSEC
Oct 2011$6 MNo. 2$2 to $10 million

Alvine Pharmaceuticals Inc.: Raise no. 2, Oct 2011

Investors in this round

6 investors had bought by the notice of Oct 21, 2011: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $12 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhay Joshi · Executive Officer, Director
  • Daniel Patrick Adelman · Executive Officer
  • David Southern · Executive Officer
  • James Patrick Watson · Executive Officer
  • Chaitan Khosla · Director
  • Gaurav Patrick Aggarawal · Director
  • Ilan Patrick Zipkin · Director
  • L. Patrick Gage · Director
  • Michael Patrick Powell · Director
  • Nina Patrick Kjellson · Director
  • William Patrick Ringo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Funds to be used for working capital.”

Signed by David Southern, Treasurer. Source: SEC Form D, newest notice filed Oct 21, 2011. Read the notice at the SEC.

debt, optionsSEC
Sep 2009$27 MNo. 1$10 to $50 million

Alvine Pharmaceuticals Inc.: Raise no. 1, Sep 2009

Investors in this round

18 investors had bought by the notice of Mar 10, 2011: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhay Joshi · Executive Officer, Director
  • David Southern · Executive Officer
  • Bill Patrick Ringo · Director
  • Chaitan Khosla · Director
  • Gaurav Patrick Aggarawal · Director
  • Ilan Patrick Zipkin · Director
  • L. Patrick Gage · Director
  • Mike Patrick Powell · Director
  • Nina Patrick Kjellson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Southern, Senior Director, Finance. Source: SEC Form D and 1 amendment, newest notice filed Mar 10, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alvine Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2013).

    SEC Form D · Jan 2013

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2013

That is all the official record says: Alvine Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Alvine Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 18 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alvine Pharmaceuticals Inc.
NameRoleNamed in
Abhay JoshiExecutive officerJan 2013
David SouthernExecutive officerJan 2013
Daniel Patrick AdelmanExecutive officerOct 2011
James Patrick WatsonExecutive officerOct 2011
Chaitan KhoslaExecutive officerSep 2009
Abhay JoshiDirectorJan 2013
Chaitan KhoslaDirectorJan 2013
David Patrick SchnellDirectorJan 2013
Gaurav AggarawalDirectorJan 2013
L. Patrick GageDirectorJan 2013
Michael Patrick PowellDirectorJan 2013
Nina Patrick KjellsonDirectorJan 2013
William Patrick RingoDirectorJan 2013
Gaurav Patrick AggarawalDirectorOct 2011
Ilan Patrick ZipkinDirectorOct 2011
Bill Patrick RingoDirectorMar 2011
Mike Patrick PowellDirectorMar 2011
Ilan ZipkinDirectorSep 2009
Michael PowellDirectorSep 2009
Nina KjellsonDirectorSep 2009
William RingoDirectorSep 2009